Get the Stockscreener App
11.20
2.28%
0.25
Pre-market:
11.20
Transcode Therapeutics Inc stock is traded at $11.20, with a volume of 15,452.
It is up +2.28% in the last 24 hours and up +4.19% over the past month.
TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.
See More
Previous Close:
$10.95
Open:
$11.33
24h Volume:
15,452
Relative Volume:
0.11
Market Cap:
$9.34M
Revenue:
-
Net Income/Loss:
$-14.93M
P/E Ratio:
-0.0421
EPS:
-266.137
Net Cash Flow:
$-15.87M
1W Performance:
-16.36%
1M Performance:
+4.19%
6M Performance:
-1.62%
1Y Performance:
-97.39%
1-Day Range:
$10.98
$11.33
1-Week Range:
$10.90
$13.96
52-Week Range:
$6.1478
$504.97
Transcode Therapeutics Inc Stock (RNAZ) Company Profile
Name
Transcode Therapeutics Inc
Sector
Industry
Phone
857-301-6857
Address
6 LIBERTY SQUARE, BOSTON
Compare RNAZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNAZ
Transcode Therapeutics Inc
|
11.20 | 10.04M | 0 | -14.93M | -15.87M | -266.14 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Transcode Therapeutics Inc Stock (RNAZ) Latest News
Why TransCode Therapeutics Inc. stock could be next big winnerPortfolio Return Report & High Yield Equity Trading Tips - newser.com
What to do if you’re stuck in TransCode Therapeutics Inc.Quarterly Performance Summary & Fast Moving Trade Plans - newser.com
TransCode Therapeutics Inc. recovery potential after sell off2025 Retail Activity & Real-Time Price Movement Reports - newser.com
How TransCode Therapeutics Inc. stock reacts to job market dataTrade Analysis Summary & Scalable Portfolio Growth Ideas - newser.com
Forecasting TransCode Therapeutics Inc. price range with options data2025 Risk Factors & Free Fast Entry Momentum Trade Alerts - newser.com
What’s the recovery path for long term holders of TransCode Therapeutics Inc.2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Market reaction to TransCode Therapeutics Inc.’s recent newsGDP Growth & AI Forecast Swing Trade Picks - newser.com
Is TransCode Therapeutics Inc. stock oversold or undervaluedTrade Risk Assessment & Low Drawdown Investment Ideas - newser.com
Is a relief rally coming for TransCode Therapeutics Inc. holders2025 Biggest Moves & Precise Entry and Exit Recommendations - newser.com
Can swing trading help recover from TransCode Therapeutics Inc. losses2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
What technical models suggest about TransCode Therapeutics Inc.’s comeback2025 Valuation Update & High Yield Stock Recommendations - newser.com
Is TransCode Therapeutics Inc. stock attractive for growth ETFs2025 Risk Factors & Weekly Watchlist for Consistent Profits - newser.com
Why TransCode Therapeutics Inc. stock is considered a top pickWeekly Stock Recap & AI Driven Price Predictions - newser.com
What MACD and RSI say about TransCode Therapeutics Inc.Bull Run & Safe Capital Growth Plans - newser.com
How to manage a losing position in TransCode Therapeutics Inc.Market Movers & Growth Focused Stock Pick Reports - newser.com
Why retail investors favor TransCode Therapeutics Inc. stock2025 Market WrapUp & Free Technical Confirmation Trade Alerts - newser.com
Using Python tools to backtest TransCode Therapeutics Inc. strategiesStop Loss & Long-Term Growth Stock Strategies - newser.com
Transcode Therapeutics Inc Stock (RNAZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):